The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up, according to BioSpace.
The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Novartis won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of the malaria drug hydroxychloroquine against COVID-19 disease to see if the medicine helps patients.
Roche won the U.S. Food and Drug Administration’s breakthrough therapy tag for Gazyva in lupus nephritis, boosting the Swiss drugmaker’s efforts to recycle the 2013-approved lymphoma medicine for new indications.
A new report released by researchers at Yale University could change the way some HIV patients are treated.